CV Sciences, Inc. Reports Third Quarter-End 2026 Financial Results

CV Sciences, Inc. (CVSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CV Sciences, Inc. Reports Third Quarter-End 2026 Financial Results San Diego, CA - November 12, 2026 (ACCESS Newswire) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp ex

Event · Earnings
Original reporting
Published Nov 12, 2026, 9:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CVSI
Bearish
high confidence
Mentioned
$CVSI
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CVSIBearishMed
01

Why it matters

Earnings miss may trigger short‑covering or further sell‑offs; however, margin improvement and product diversification provide a modest upside narrative.

02

Market read

Micro‑cap earnings release with modest financial improvement but revenue decline; likely limited market impact.

03

What to watch

Potential upside from new product launches (48% of revenue) and upcoming regulatory updates in December.

Relevance 7/10Novelty 7/10Timing: released today

Background

CV Sciences is an OTC‑listed consumer wellness company focused on hemp extracts. The Q3 2026 filing includes a legal settlement gain and cost reductions.

Company-level read

Ticker impact

$CVSIBearishHigh confidence
Context

CV Sciences reported Q3 2026 results with revenue down 7% YoY and positive adjusted EBITDA of $32k.

Expected impact

likely downward pressure as investors price in lower revenue and regulatory headwinds

Evidence & confidence

Revenue decline and ongoing regulatory challenges suggest limited upside; the modest EBITDA improvement is unlikely to offset the top‑line weakness.

Market effects

Highlights continued pressure on the hemp‑derived wellness sector from federal regulation.

May affect other OTC wellness companies facing similar regulatory scrutiny.

Limited; primarily a micro‑cap US OTC issue.

Counterpoint

The positive adjusted EBITDA and margin expansion could signal a turnaround if regulatory environment eases.

Key entities

  • Joseph Dowling

    CEO of CV Sciences who commented on the Q3 results.

Related articles

$CVSIMed

CV Sciences, Inc. Reports Second Quarter-End 2026 Financial Results

CV Sciences, Inc. (CVSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CV Sciences, Inc. Reports Second Quarter-End 2026 Financial Results San Diego, CA - August 13, 2026 (ACCESS Newswire) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp ext

$SLNHMed

Soluna Q3 Earnings Call Highlights

Soluna reported a Q3 gross loss of $1.9M, impacted by $3M in wind turbine repairs. Revenue was $12.4M, with mining revenue down 33%. The company has $109.3M in cash and $7.7M in debt post-repayment. Soluna formed a joint venture with Applied Digital for a 50MW facility, with closing expected by early December. Future AI projects may use 70-80% debt financing.

$NIUMed

Niu Tech (NIU) Q3 2026 Earnings Call Transcript

Niu Tech (NIU) reported Q3 2026 earnings, with total sales volume up 15.4% YoY to 534,057 units. Revenue was RMB 1.71 billion, up 1.2% YoY. China sales grew 8.6% YoY, while international sales surged 226%. Gross margin expanded to 18.0%. The company highlighted strong growth in electric motorcycles, which accounted for 56% of China sales, and strategic product launches.